Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $1.50 on Tuesday. The stock’s 50 day moving average price is $1.11 and its two-hundred day moving average price is $1.78. Akari Therapeutics has a 52-week low of $0.85 and a 52-week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.